Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsPreferred Shares IssuedProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Other Gross PP&E Adjustments (2016 - 2026)

Viridian Therapeutics, Inc.\DE has reported Other Gross PP&E Adjustments over the past 12 years, most recently at -$11.8 million for Q4 2025.

  • Quarterly results put Other Gross PP&E Adjustments at -$11.8 million for Q4 2025, down 59.87% from a year ago — trailing twelve months through Dec 2025 was -$11.8 million (down 59.87% YoY), and the annual figure for FY2025 was -$11.8 million, down 59.87%.
  • Other Gross PP&E Adjustments for Q4 2025 was -$11.8 million at Viridian Therapeutics, Inc.\DE, down from -$700000.0 in the prior quarter.
  • Over the last five years, Other Gross PP&E Adjustments for VRDN hit a ceiling of $654000.0 in Q3 2021 and a floor of -$14.0 million in Q4 2023.
  • Median Other Gross PP&E Adjustments over the past 5 years was -$1.7 million (2022), compared with a mean of -$2.7 million.
  • Biggest five-year swings in Other Gross PP&E Adjustments: crashed 592.97% in 2022 and later surged 83.83% in 2024.
  • Viridian Therapeutics, Inc.\DE's Other Gross PP&E Adjustments stood at -$2.7 million in 2021, then rose by 7.96% to -$2.4 million in 2022, then plummeted by 471.98% to -$14.0 million in 2023, then soared by 46.93% to -$7.4 million in 2024, then plummeted by 59.87% to -$11.8 million in 2025.
  • The last three reported values for Other Gross PP&E Adjustments were -$11.8 million (Q4 2025), -$700000.0 (Q3 2025), and -$2.0 million (Q2 2025) per Business Quant data.